These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28257549)

  • 1. Analysis of Intensive Care Unit Admission and Sequelae in Patients Intravenously Abusing Extended-Release Oral Oxymorphone.
    Wilson MW; Bonnecaze AK; Dharod A; Miller PJ
    South Med J; 2017 Mar; 110(3):217-222. PubMed ID: 28257549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute kidney injury is common with intravenous abuse of extended-release oral oxymorphone and delayed renal recovery rates are associated with increased KDIGO staging.
    Bonnecaze AK; Wilson MW; Dharod A; Fletcher A; Miller PJ
    Nephrology (Carlton); 2018 Oct; 23(10):921-926. PubMed ID: 28802086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxymorphone Hydrochloride Extended-Release (OPANA®) Associated With Acute Kidney Injury in a Chronic Pain Patient: A Case Report.
    Yatsynovich Y; Souza D; Maroz N
    A A Case Rep; 2017 Dec; 9(11):324-327. PubMed ID: 28786851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic microangiopathy and acute kidney injury associated with intravenous abuse of an oral extended-release formulation of oxymorphone hydrochloride: kidney biopsy findings and report of 3 cases.
    Ambruzs JM; Serrell PB; Rahim N; Larsen CP
    Am J Kidney Dis; 2014 Jun; 63(6):1022-6. PubMed ID: 24529995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
    Cassidy TA; DasMahapatra P; Black RA; Wieman MS; Butler SF
    Pain Med; 2014 Mar; 15(3):440-51. PubMed ID: 24330279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opana ER abuse and thrombotic thrombocytopenic purpura (TTP)-like illness: a rising risk factor in illicit drug users.
    Kapila A; Chhabra L; Chaubey VK; Summers J
    BMJ Case Rep; 2014 Mar; 2014():. PubMed ID: 24591390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombotic microangiopathy associated with intravenous injection of extended-release oxycodone.
    Robson KJ; Clucas D; Filshie R; Nandurkar H
    BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28716778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid associated intravenous and cutaneous microvascular drug abuse (skin-popping) masquerading as Degos disease (malignant atrophic papulosis) with multiorgan involvement.
    Magro CM; Toledo-Garcia A; Pala O; Momtahen S; Shapiro L
    Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. THROMBOTIC MICROANGIOPATHY ASSOCIATED WITH OPANA ER INTRAVENOUS ABUSE A Case Report.
    Jabr FI; Yu L
    J Med Liban; 2016; 64(1):40-2. PubMed ID: 27169165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER.
    Hunt R; Yalamanoglu A; Tumlin J; Schiller T; Baek JH; Wu A; Fogo AB; Yang H; Wong E; Miller P; Buehler PW; Kimchi-Sarfaty C
    Blood; 2017 Feb; 129(7):896-905. PubMed ID: 27864296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Sensorineural Hearing Loss After Abuse of an Inhaled, Crushed Oxymorphone Extended-Release Tablet.
    MacDonald LE; Onsrud JE; Mullins-Hodgin R
    Pharmacotherapy; 2015 Jul; 35(7):e118-21. PubMed ID: 26112082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse--Tennessee, 2012.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Jan; 62(1):1-4. PubMed ID: 23302815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral extended-release oxymorphone: a new choice for chronic pain relief.
    Matsumoto AK
    Expert Opin Pharmacother; 2007 Jul; 8(10):1515-27. PubMed ID: 17661733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs.
    Cicero TJ; Ellis MS; Kasper ZA
    Pain; 2016 Jun; 157(6):1232-1238. PubMed ID: 27186712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy.
    Bucher Bartelson B; Le Lait MC; Green JL; Cepeda MS; Coplan PM; Maziere JY; Wedin GP; Dart RC
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1061-1070. PubMed ID: 28758289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
    Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
    J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting acceptability of titrated oxymorphone extended release in chronic low back pain - an individual patient analysis.
    Peniston JH; Xiang Q; Gould EM
    Curr Med Res Opin; 2010 Aug; 26(8):1861-71. PubMed ID: 20521870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH; Gould E
    Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
    Hale ME; Ahdieh H; Ma T; Rauck R;
    J Pain; 2007 Feb; 8(2):175-84. PubMed ID: 17145204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple injections per injection episode: High-risk injection practice among people who injected pills during the 2015 HIV outbreak in Indiana.
    Broz D; Zibbell J; Foote C; Roseberry JC; Patel MR; Conrad C; Chapman E; Peters PJ; Needle R; McAlister C; Duwve JM
    Int J Drug Policy; 2018 Feb; 52():97-101. PubMed ID: 29278838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.